<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00078897</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000353185</org_study_id>
    <secondary_id>P30CA023074</secondary_id>
    <secondary_id>P01CA041108</secondary_id>
    <nct_id>NCT00078897</nct_id>
  </id_info>
  <brief_title>Selenium for Prevention of Adenomatous Colorectal Polyps</brief_title>
  <official_title>Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
      development or recurrence of cancer. Selenium may be effective in preventing the recurrence
      of adenomatous colorectal polyps.

      PURPOSE: This randomized phase III trial is studying selenium to see how well it works in
      preventing the recurrence of polyps in patients with adenomatous colorectal polyps.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the effects of selenium vs placebo on the recurrence of adenomatous colorectal
           polyps, in terms of histologic type, degree of dysplasia, number, size, and location, in
           patients with adenomatous colorectal polyps.

        -  Compare the type, incidence, and outcome of side effects in patients treated with these
           regimens.

        -  Determine patient adherence to long-term treatment with these regimens.

      Secondary

        -  Determine the effects of regimen modification by baseline blood selenium level, low-dose
           aspirin, selenoprotein genetic marker polymorphisms (e.g., GPx-1, GPx-2, and SEP15)

        -  Determine the effects of low-dose aspirin (81 mg/day) modification by ornithine
           decarboxylase promoter genotype, and toxicity by slow-metabolizer genotypes of the
           cytochrome p450 2C9 and UT1A6 loci in these patients.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to use of low-dose (≤ 81 mg/day) aspirin (yes vs no). Patients are
      randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral selenium once daily.

        -  Arm II: Patients receive oral placebo once daily. In both arms, treatment continues for
           up to 5 years* in the absence of disease progression or unacceptable toxicity.

      Patients undergo follow-up colonoscopy approximately 5 years* after baseline colonoscopy.

      NOTE: Some patients will continue participation for up to 7 and a half years

      PROJECTED ACCRUAL: A total of 1,600 patients with an adenoma will be randomized to this
      study, followed by a second group of randomization of 200 patients with at least one advanced
      adenoma (at baseline) for a substudy. Total planned randomizations = 1,800 participants.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Concluded - Terminated by PI
  </why_stopped>
  <start_date type="Actual">January 20, 2005</start_date>
  <completion_date type="Actual">May 17, 2018</completion_date>
  <primary_completion_date type="Actual">January 7, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Recurrent Adenomas at Surveillance Colonoscopy</measure>
    <time_frame>3 to 5 years after baseline colonoscopy</time_frame>
    <description>Detection of metachronous colorectal adenomas during follow-up, by treatment, in the original cohort. Surveillance colonoscopy is recommended 3 to 5 years after removal of colorectal adenoma(s). Participants will remain on the study intervention until their surveillance colonoscopy. Surveillance colonoscopy is determined by participants' GI physician.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Selenium Blood Levels at One Year.</measure>
    <time_frame>One year</time_frame>
    <description>Adequate adherence to long-term selenium treatment as measured by blood selenium levels (ng/mL) at one year.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1621</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Adenomatous Colorectal Polyps</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Selenium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive oral selenium 200 mcg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive oral placebo once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selenium</intervention_name>
    <description>Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Selenium</arm_group_label>
    <other_name>SelenoExcell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed colorectal adenomatous polyps

          -  Meets the following criteria by colonoscopy (performed within the past 6 months):

               -  Cecum was totally visualized or reached

               -  At least 90% visualization of colon surface area

               -  Removed at least 1 adenomatous polyp of at least 3 mm in size during procedure
                  (For the Advanced Adenoma Sub-study: Removal of at least 1 advanced colorectal
                  adenomatous polyp during procedure. An adenoma is considered advanced if it is 10
                  mm or greater in size, and/or has villous histology and/or shows high grade
                  dysplasia)

               -  Removed no more than 10 adenomatous polyps of any size by endoscopy

               -  All other neoplastic and non-neoplastic colon polyps must have been completely
                  removed (except for diminutive [less than 3 mm] sessile rectal polyps)

               -  For the sub-study, at least 1 advanced adenomatous polyp defined as 10 mm or
                  greater in size and/or has villous histology and/or shows high grade dysplasia

          -  No prior diagnosis of any of the following:

               -  Colorectal cancer

               -  Familial adenomatous polyposis

               -  Ulcerative colitis

               -  Crohn's disease

               -  Hereditary non-polyposis colon cancer (HNPCC), defined as:

                    -  Histologically confirmed colorectal cancer in at least 3 relatives, 1 of
                       whom is a first-degree relative of the other 2

                    -  Disease occurrence in at least 2 consecutive generations

                    -  Colorectal cancer diagnosis in at least 1 family member who is less than 50
                       years of age

                         -  Patients with a family history of colorectal cancer but who are not
                            diagnosed with HNPCC are allowed

          -  No more than 1 prior segmental colon resection

        PATIENT CHARACTERISTICS:

        Age

          -  40 to 80

        Performance status

          -  SWOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Hemoglobin &gt; 11 g/dL

          -  WBC 3,000 - 11,000/mm^3

        Hepatic

          -  AST and ALT &lt; 2 times upper limit of normal

          -  Bilirubin &lt; 2.0 mg/dL

        Renal

          -  Creatinine &lt; 1.9 mg/dL

        Cardiovascular

          -  No unstable* cardiac disease despite medication (e.g., diuretics or digitalis)

          -  No uncontrolled hypertension (i.e., systolic blood pressure ≥ 170 mm Hg and/or
             diastolic blood pressure ≥ 110 mm Hg) despite medication NOTE: *Unstable defined as
             unable to walk across the room without chest pain or shortness of breath

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception for at least 2 months before and
             during study treatment

          -  Resident of a clinical center metropolitan area or obtaining regular health care in a
             clinical metropolitan area for at least 6 months out of the year

          -  Must be able to swallow pills

          -  No unexpected weight loss of 10% or more within the past 6 months

          -  No prior rheumatoid arthritis

          -  No poorly controlled diabetes mellitus despite medication, defined as:

               -  Blood sugar level ≥ 200 mg/dL on more than half of the readings taken within the
                  past month

          -  No invasive malignancy within the past 5 years that required medical excision,
             radiotherapy, or chemotherapy except basal cell or squamous cell carcinoma

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent drugs that regulate the immune system

        Chemotherapy

          -  No concurrent chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  See Disease Characteristics

        Other

          -  Prior enrollment in another adenoma prevention study allowed

          -  Concurrent routine aspirin (≤ 81 mg/day) allowed

          -  No regular use of non-steroidal anti-inflammatory drugs (NSAIDs)

          -  No concurrent enrollment in another research study using pharmacological cancer drugs,
             a cyclo-oxygenase-2 inhibitor, or selenium

          -  No other concurrent selenium unless dosage is ≤ 50 µg/day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Peter Lance, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258-4512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center - Tucson Clinic</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at UC Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoscopy Center of Western New York</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272807/</url>
    <description>Journal Article</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2004</study_first_posted>
  <results_first_submitted>July 15, 2019</results_first_submitted>
  <results_first_submitted_qc>September 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2019</results_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>adenomatous polyp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Adenomatous Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through clinical centers in Arizona, Colorado, Texas, and New York following ambulatory colonoscopies. Eligible participants were between age 40 and 80 years and had undergone colonoscopic removal of one or more colorectal adenomas 3 mm or larger within six months prior to random assignment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Selenium</title>
          <description>Participants receive oral selenium 200 mcg once daily.
Selenium: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants receive oral placebo once daily.
Selenium: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="809"/>
                <participants group_id="P2" count="812"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="685"/>
                <participants group_id="P2" count="689"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Selenium</title>
          <description>Participants receive oral selenium 200 mcg once daily.
Selenium: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants receive oral placebo once daily.
Selenium: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="685"/>
            <count group_id="B2" value="689"/>
            <count group_id="B3" value="1374"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="8.9"/>
                    <measurement group_id="B2" value="63.1" spread="8.7"/>
                    <measurement group_id="B3" value="63.4" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="476"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="443"/>
                    <measurement group_id="B2" value="455"/>
                    <measurement group_id="B3" value="898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="660"/>
                    <measurement group_id="B2" value="650"/>
                    <measurement group_id="B3" value="1310"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="652"/>
                    <measurement group_id="B2" value="650"/>
                    <measurement group_id="B3" value="1302"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="685"/>
                    <measurement group_id="B2" value="689"/>
                    <measurement group_id="B3" value="1374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Recurrent Adenomas at Surveillance Colonoscopy</title>
        <description>Detection of metachronous colorectal adenomas during follow-up, by treatment, in the original cohort. Surveillance colonoscopy is recommended 3 to 5 years after removal of colorectal adenoma(s). Participants will remain on the study intervention until their surveillance colonoscopy. Surveillance colonoscopy is determined by participants' GI physician.</description>
        <time_frame>3 to 5 years after baseline colonoscopy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Selenium</title>
            <description>Participants receive oral selenium 200 mcg once daily.
Selenium: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants receive oral placebo once daily.
Selenium: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Recurrent Adenomas at Surveillance Colonoscopy</title>
          <description>Detection of metachronous colorectal adenomas during follow-up, by treatment, in the original cohort. Surveillance colonoscopy is recommended 3 to 5 years after removal of colorectal adenoma(s). Participants will remain on the study intervention until their surveillance colonoscopy. Surveillance colonoscopy is determined by participants' GI physician.</description>
          <units>Adenomas</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="685"/>
                <count group_id="O2" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                    <measurement group_id="O2" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Selenium Blood Levels at One Year.</title>
        <description>Adequate adherence to long-term selenium treatment as measured by blood selenium levels (ng/mL) at one year.</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Selenium</title>
            <description>Participants receive oral selenium 200 mcg once daily.
Selenium: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants receive oral placebo once daily.
Selenium: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Selenium Blood Levels at One Year.</title>
          <description>Adequate adherence to long-term selenium treatment as measured by blood selenium levels (ng/mL) at one year.</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="685"/>
                <count group_id="O2" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.4" lower_limit="100.7" upper_limit="367.6"/>
                    <measurement group_id="O2" value="140.0" lower_limit="84.9" upper_limit="270.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Negative binomial regression</non_inferiority_desc>
            <p_value>0.68</p_value>
            <method>Negative binomial regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Selenium</title>
          <description>Participants receive oral selenium 200 mcg once daily.
Selenium: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants receive oral placebo once daily.
Selenium: Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation/arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Misc. cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Misc. ear and labyrinth disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Misc. endocrine disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Acute appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>GI Bleed</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Misc. GI disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Miscellaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Misc. hepatobiliary disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Misc. metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Arthritis/Degenerative joint disease</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Misc. musculoskeletal disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Misc. neoplasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke/Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Syncope/dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Misc. nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Misc. psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Misc. renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Misc. reproductive and breast disorders</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Misc. respiratory disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Misc. vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="685"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Elizabeth Jacobs</name_or_title>
      <organization>University of Arizona</organization>
      <phone>(520) 626-0341</phone>
      <email>jacobse@email.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

